EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Spero Therapeutics's enterprise value is $6.28 Mil.
Spero Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $96.74 Mil. Therefore, Spero Therapeutics's EV-to-Revenue for today is 0.06.
The historical rank and industry rank for Spero Therapeutics's EV-to-Revenue or its related term are showing as below:
SPRO'
s EV-to-Revenue Range Over the Past 10 Years
Min: -447.84 Med: 0.09 Max: 1720.37
Current: 0.06
During the past 9 years, the highest EV-to-Revenue of Spero Therapeutics was 1720.37. The lowest was -447.84. And the median was 0.09.
SPRO's EV-to-Revenue is ranked better than 91.38% of 1032
companies
in the Biotechnology industry
Industry Median: 7.64
vs SPRO: 0.06
As of today (2024-04-24), Spero Therapeutics's stock price is $1.42.
Spero Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.80. Therefore, Spero Therapeutics's PS Ratio for today is 0.79.
Spero Therapeutics EV-to-Revenue Historical Data
The historical data trend for Spero Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spero Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Spero Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's EV-to-Revenue falls into.
Spero Therapeutics's current Enterprise Value is $6.28 Mil.
Spero Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $96.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics's share price for today is $1.42.
Spero Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Spero Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Spero Therapeutics (Spero Therapeutics) Business Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPRO has been successfully added to your 